Immunogenicity of a heptavalent conjugate pneumococcal vaccine administered concurrently with a combination diphtheria, tetanus, five-component acellular pertussis, inactivated polio, and Haemophilus influenzae type b vaccine and a meningococcal group C conjugate vaccine at 2, 3, and 4 months of age

Clinical and Vaccine Immunology

Volumn 17, Issue 3, 2010, Pages 311-316

  Moss, S J ^a   Fenton, A C ^a   Toomey, J ^b   Grainger, A ^b   Borrow, R ^c   Balmer, P ^c   Smith, J ^a   Gennery, A R ^b  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TOXIN; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; INACTIVATED VACCINE; MENINGOCOCCUS VACCINE; PEDIACEL; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; GEOMETRY; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; NORMAL HUMAN; PRIORITY JOURNAL; SEROTYPE;

ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; HAEMOPHILUS VACCINES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INFANT; MENINGOCOCCAL VACCINES; PNEUMOCOCCAL VACCINES; POLIOVIRUS VACCINES; VACCINES, COMBINED;

EID: 77649260036     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00315-09     Document Type: Article

References (19)

1. Andrews, N., R. Borrow, and E. Miller. 2003. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin. Diagn. Lab. Immunol. 10:780-786.
2. Berrington, J. E., A. J. Cant, J. N. Matthews, M. O'Keeffe, G. P. Spickett, and A. C. Fenton. 2006. Haemophilus influenzae type b immunization in infants in the United Kingdom: effects of diphtheria/tetanus/acellular pertussis/Hib combination vaccine, significant prematurity, and a fourth dose. Pediatrics 117:e717-e724.
3. Black, S., H. Shinefield, B. Fireman, E. Lewis, P. Ray, J. R. Hansen, L. Elvin, K. M. Ensor, J. Hackell, G. Siber, F. Malinoski, D. Madore, I. Chang, R. Kohberger, W. Watson, R. Austrian, K. Edwards, J. Aguilar, M. Bartlett, R. Bergen, M. Burman, S. Dorfman, W. Easter, A. Finkel, H. Froehlich, J. Glauber, A. Herz, D. Honeychurch, R. Kleinrock, I. Landaw, A. Lavetter, C. Le, S. McMurtry, P. Morozumi, P. Mullin, M. Rehbein, R. Rossin, G. Soe, I. Takahashi, G. Udkow, and R. Whitson. 2000. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr. Infect. Dis. J. 19:187-195.
4. Borrow, R., and E. B. Kaczmarksi. 2000. Meningococcal serology, p. 289-304. In A. J. Pollard and M. C. J. Maiden (ed.), Methods in molecular medicine. Human Press, Totowa, NJ.
5. Buttery, J. P., A. Riddell, J. McVernon, T. Chantler, L. Lane, J. Bowen-Morris, L. Diggle, R. Morris, A. Harnden, S. Lockhart, A. J. Pollard, K. Cartwright, and E. R. Moxon. 2005. Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial. JAMA 293:1751-1758.
6. Carlone, G. M., C. E. Frasch, G. R. Siber, S. Quataert, L. L. Gheesling, S. H. Turner, B. D. Plikaytis, L. O. Helsel, W. E. DeWitt, W. F. Bibb, et al. 1992. Multicenter comparison of levels of antibody to the Neisseria meningitidis group A capsular polysaccharide measured by using an enzyme-linked immunosorbent assay. J. Clin. Microbiol. 30:154-159.
7. Choo, S., L. Seymour, R. Morris, S. Quataert, S. Lockhart, K. Cartwright, and A. Finn. 2000. Immunogenicity and reactogenicity of a pneumococcal conjugate vaccine administered combined with a Haemophilus influenzae type B conjugate vaccine in United Kingdom infants. Pediatr. Infect. Dis. J. 19:854-862.
8. CMO. 2002, posting date. Pneumococcal vaccine for at-risk under 2 year olds. http://www.dh.gov.uk/en/publicationsandstatistics/ Lettersandcirculars/Professionalletters/chiefpharmaceuticalofficerletters/ DH-4004729.
9. Goldblatt, D., J. Southern, L. Ashton, P. Richmond, P. Burbidge, J. Tasevska, A. Crowley-Luke, N. Andrews, R. Morris, R. Borrow, K. Cartwright, and E. Miller. 2006. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr. Infect. Dis. J. 25:312-319.
10. Health Protection Agency. 2007, posting date. Pneumococcal serotype distribution for samples referred for serotyping epidemiological years (June). Health Protection Agency, Manchester, United Kingdom. 2000/1-2005/6 www.hpa.org.uk/infections.
11. Kitchin, N. R., J. Southern, R. Morris, F. Hemme, S. Thomas, M. W. Watson, K. Cartwright, and E. Miller. 2007. Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Arch. Dis. Child. 92:11-16.
12. Lockhart, S. P., J. G. Hackell, and B. Fritzell. 2006. Pneumococcal conjugate vaccines: emerging clinical information and its implications. Expert Rev. Vaccines 5:553-564.
13. Maslanka, S. E., L. L. Gheesling, D. E. Libutti, K. B. Donaldson, H. S. Harakeh, J. K. Dykes, F. F. Arhin, S. J. Devi, C. E. Frasch, J. C. Huang, P. Kriz-Kuzemenska, R. D. Lemmon, M. Lorange, C. C. Peeters, S. Quataert, J. Y. Tai, and G. M. Carlone. 1997. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin. Diagn. Lab. Immunol. 4:156-167.
14. Moss, S. J., A. C. Fenton, and A. R. Gennery. 2005. Use of conjugate pneumococcal vaccine by United Kingdom neonatal intensive care units. Arch. Dis. Child. Fetal Neonatal Ed. 90:F187-F188.
15. Phipps, D. C., J. West, R. Eby, M. Koster, D. V. Madore, and S. A. Quataert. 1990. An ELISA employing a Haemophilus influenzae type b oligosaccharide-human serum albumin conjugate correlates with the radioantigen binding assay. J. Immunol. Methods 135:121-128.
16. Reinert, P., M. Guy, B. Girier, B. Szelechowski, B. Baudoin, P. Deberdt, A. Wollner, G. Kemeny, M. Amzallag, C. Moat, C. Szelechowski, H. Villain-Lemoine, C. A. Bouhanna, and F. Laudat. 2003. The safety and immunogenicity of an heptavalent pneumococcal polysaccharide conjugate vaccine (Prevenar) administered in association with a whole-cell pertussis-based pediatric combination vaccine (DTP-IPV/PRP-T) to French infants with a two-, three-, and four-month schedule. Arch. Pediatr. 10:1048-1055. (In French.)
17. Ruggeberg, J. U., C. Collins, P. Clarke, N. Johnson, R. Sinha, N. Everest, J. Chang, E. Stanford, P. Balmer, R. Borrow, S. Martin, M. J. Robinson, E. R. Moxon, A. J. Pollard, and P. T. Heath. 2007. Immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infants. Vaccine 25:264-271.
18. Schmitt, H. J., J. Faber, I. Lorenz, A. B. Schmöle-Thoma, and N. Ahlers. 2003. The safety, reactogenicity and immunogenicity of a 7-valent pneumococcal conjugate vaccine (7VPnC) concurrently administered with a combination DTaP-IPV-Hib vaccine. Vaccine 21:3653-3662.
19. WHO. 2005. Recommendations for the production and control of pneumoccocal conjugate vaccines. World Health Organ. Tech. Rep. Ser. 927:2007.